TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02276040

Intervention type: DRUG
Intervention: periarticular bupivicaine and liposomal bupivicaine
Description: Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
Study: NCT02474173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02568319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02015130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual treatment
Description: See detailed description
Study: NCT02567903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thigh Tourniquet
Description: Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee arthroscopy
Description: Knee arthroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee arthroscopy
Description: Knee arthroscopy
Study: NCT04386746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1g gemcitabine in 50ml sterile water; instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 37.5mg docetaxel in 50ml normal saline solution (NSS); instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.
Study: NCT02703727

Intervention type: BEHAVIORAL
Intervention: Extended polymedication check
Description: Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer.
Study: NCT04765943

Intervention type: DEVICE
Intervention: Implantable Loop Recorder implant
Description: Patients will be undergone to an Implantable Loop Recorder implant and monitored for the next 6 months.They will then undergo a cardiac MRI and an ICD will be implanted according to clinical practice guidelines. A minimum follow-up of 2 years is scheduled.
Study: NCT02276131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vigilant Diabetes Management Application
Description: Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
Study: NCT03916926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A simple medical strategy consisting of silver diamine fluoride (SDF)
Description: Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride varnish (FV)
Description: GC Fuji (for ART) and FluoriMax Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL (for FV)
Study: NCT00643838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kalinox 170 bar
Description: Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
Study: NCT04208737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recruitment maneuver
Description: 30 cmH2O pressure 15 seconds
Study: NCT02047461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORGN001 (formerly ALXN1101)
Description: IV infusion
Study: NCT03270930

Intervention type: PROCEDURE
Intervention: Emergency laparotomy
Description: All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.

Intervention type: PROCEDURE
Intervention: Emergency laparotomy
Description: All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
Study: NCT01971918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti drug antibodies dosage
Description: anti drug antibodies dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti drug antibodies dosage
Description: anti drug antibodies dosage
Study: NCT03828695

Intervention type: OTHER
Group type: OTHER
Intervention: uterocervical angle
Description: uterocervical angle is the angle between lower segment of uterus and cervix
Study: NCT04109690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
Study: NCT02892799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICOM-Guided Diuresis
Description: NICOM-based assessment of PLR-induced change in cardiac index

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study: NCT00466791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate Transdermal System
Description: Placebo
Study: NCT03365609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple therapy
Description: Omeprazole+Amoxicillin+Clarithromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sequential therapy
Description: the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bismuth quadruple therapy
Description: Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concomitant therapy
Description: Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
Study: NCT00569738

Intervention type: PROCEDURE
Intervention: PET scan with Ga68-DOTANOC
Description: Imaging: PET scan with Ga68-DOTANOC
Study: NCT02219490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin was provided as 200 mg tablets, and dosed based on weight,1000 to 1200 mg divided twice daily per local label. For example, for participants weighing \< 75 kg, RBV may have been taken orally as 2 tablets in the morning and 3 tablets in the evening which corresponds to a 1000 mg total daily dose. For participants weighing ≥ 75 kg, RBV may have been taken orally as 3 tablets in the morning and 3 tablets in the evening which corresponds to a 1200 mg total daily dose.
Study: NCT02274402

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: Blood sample of 4 ml at enrolment and then at two following visits
Study: NCT00261547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
Study: NCT03879642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDCHiP
Description: 10 week video-based telemedicine intervention to reduce hypoglycemia fear
Study: NCT04529993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
Study: NCT00578214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomized Midazolam
Description: Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local Anesthesia
Description: Lidocaine 1% with 1:100,000 epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Lidocaine 1% with 1:100,000 epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthesia
Description: Lidocaine 1% with 1:100,000 epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospective Midazolam
Description: Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (\>45 to 77 kg, 10 mg; \>77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
Study: NCT02824003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-GCGRRx
Description: once weekly dosing for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once weekly dosing for 13 weeks
Study: NCT02272517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram 10-20 mg
Study: NCT01002443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Helicobacter pylori eradication
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
Study: NCT00667693

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Intubation with Macintosh laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pentax AWS
Description: Intubation with Pentax AWS
Study: NCT02970461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified Group
Description: See Gamified Group in Arms description.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: See Control Group in Arms description.
Study: NCT03404843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil Hydrochloride
Description: 10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 mL saline bag.
Study: NCT00567164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP (BAY86-5300)
Description: Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP (BAY86-5300)
Description: Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE20/DRSP (YAZ, BAY86-5300)
Description: Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
Study: NCT01715909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Participants will receive standard dose (30 to 75 milligrams \[mg\]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for \</= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (\>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
Study: NCT06747026

Intervention type: DRUG
Intervention: initial Sequential iRT
Description: For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days.
Study: NCT02543216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Description: Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Description: Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
Study: NCT00545844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
Study: NCT02506426

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic sinus surgery + Septoplasty
Description: Opening of the paranasal sinuses along with correcting the nasal septum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septoplasty alone
Description: Straightening of the nasal septum without opening the paranasal sinuses
Study: NCT00001575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Y-90 Humanized Anti-Tac
Description: 10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium-DTPA
Description: Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
Study: NCT03736785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT04160689

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: implantology
Description: placing of implant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: implantology
Description: placing of implant
Study: NCT01539603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloon + Bare metal stent
Description: PCI using Sequent Please and then Coroflex Blue

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting stent (Zotarolimus-eluting stent)
Description: conventional PCI using Endeavor Integrity
Study: NCT02095158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline HCL Cream 1.0%
Description: Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
Study: NCT02956499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single dose 4
Study: NCT02770144

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to Referral to Social Services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to Referral to Social Services
Study: NCT00116480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 600 mcg of sublingual misoprostol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: 600 mcg of sublingual misoprostol
Study: NCT02956499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single dose 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 single dose 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 multiple dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 multiple dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 multiple dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 multiple dose 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Study: NCT04312568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fadanafil
Description: Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
Study: NCT03518983

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries2 device
Description: The Dornier Aries2 device and will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft and the 2 crura(two sites).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dornier Aries2 device (sham probe)
Description: The Dornier Aries2 device and will be used for the purpose of the study but the active probe will be replaced by an identical sham probe.
Study: NCT04238104

Intervention type: OTHER
Intervention: no intervention
Description: it's only observational study. No interventions.

Intervention type: OTHER
Intervention: no intervention
Description: it's only observational study. No interventions.

Intervention type: OTHER
Intervention: no intervention
Description: it's only observational study. No interventions.

Intervention type: OTHER
Intervention: no intervention
Description: it's only observational study. No interventions.

Intervention type: OTHER
Intervention: no intervention
Description: it's only observational study. No interventions.

Intervention type: OTHER
Intervention: no intervention
Description: it's only observational study. No interventions.
Study: NCT03693755

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-plane Group
Description: Placement of femoral nerve catheter under ultrasound control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-plane Group
Description: Placement of femoral nerve catheter under ultrasound control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Out-of-plane Group
Description: Placement of femoral nerve catheter under ultrasound control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Out-of-plane Group
Description: Placement of femoral nerve catheter under ultrasound control
Study: NCT03198546

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GPC3 and/or TGFβ targeting CAR-T cells
Description: Engineering GPC3 or/and TGFβ targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Tigit secreting vector into T cells with knockdown of PD1/HPK1, which are isolated from patients with advanced HCC, and then transfusing them back the patients.
Study: NCT02537392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B Complex and Folic Acid
Description: Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and Folic Acid
Description: Daily oral dose of 60 mg iron and 0.4 mg folic acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Daily oral dose of 0.4 mg folic acid.
Study: NCT01501214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atosiban
Description: Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline given
Study: NCT02380729

Intervention type: GENETIC
Intervention: Gene Panel Sequencing
Description: Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.

Intervention type: GENETIC
Intervention: Whole Genome Sequencing (WGS)
Description: Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.

Intervention type: GENETIC
Intervention: Whole Genome Sequencing (WGS)
Description: Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.